Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross-sectional study

Authors


  • Conflicts of interests
    E. Mahé is a consultant for Janssen-Cilag; has received research support by MSD; and has received speaker honoraria from Abbott, Janssen-Cilag, Pfizer, and Schering-Plough.
    Z. Reguiai is a consultant for Janssen-Cilag and Pfizer; has been an investigator for Abbott, Novartis, and Pfizer; has received speaker honoraria from Abbott, Janssen-Cilag, Pfizer and Schering-Plough.
    H. Barthelemy is a consultant for Abbott, Janssen-Cilag, Leo, MSD and Pfizer; and has received speaker honoraria from Abbott, Janssen-Cilag, Leo, MSD and Pfizer.
    N. Quiles-Tsimaratos is a consultant for Janssen-Cilag.
    G. Chaby is a consultant for Janssen-Cilag; and has received speaker honoraria from Abbott, Leo and Pfizer.
    C. Girard has received speaker honoraria from Abbott, Janssen-Cilag and Leo.
    E. Estève has received speaker honoraria from Abbott, Janssen-Cilag, Leo, Pfizer and Schering-Plough.
    F. Maccari is a consultant for Janssen-Cilag; and has received speaker honoraria from Abbott, Janssen-Cilag, Leo and Schering-Plough.
    V. Descamps has been an investigator for Pfizer and Schering-Plough; is a consultant for Pfizer; has received research support by Pfizer; and has received speaker honoraria from Abbott, Janssen-Cilag, Pfizer and MSD.
    J.-L. Schmutz has been an investigator for Pfizer.
    E. Begon has received research support by Abbott, Jansen-Cilag and Pfizer; and has received speaker honoraria from Abbott, Janssen-Cilag, Leo, MSD and Pfizer.
    P. Bravard has been an investigator for Abbott; and has received speaker honoraria from Abbott, Janssen-Cilag, Pfizer and Schering-Plough.
    H. Maillard has been an investigator for Pfizer; is a consultant for Janssen-Cilag; and has received speaker honoraria from Janssen-Cilag.
    T. Boyé has received speaker honoraria from Abbott and Janssen-Cilag.
    M.-L. Sigal has received speaker honoraria from Janssen-Cilag.
    A. Beauchet declares no conflict of interest concerning this article.
    Authors thank Martine Avenel-Audran (Angers), Guido Bens (Orléans), Laure Mery-Bossard (Mantes-La-Jolie), Mireille Ruer-Mulard (Martigues), Henri-Georges Steiner (Vienne) and Annie Vermersch-Langlin (Valenciennes) for their kind collaboration.

  • Funding sources
    None declared.

Abstract

Background  A significant weight gain has been reported in patients with psoriasis treated with anti-tumour necrosis factor-alpha agents. Among these patients, there are contradictory results about risk factors for weight gain.

Objective  Assessing risk factors for weight increment in psoriatic patients on infliximab (IFX).

Methods  This study was a 4-month, non-interventional, cross-sectional, multicentre study on adults with psoriasis performed in 19 French dermatological centres. All the patients who received IFX for at least 1 year were prospectively included, with retrospective analysis of data. Impact of sex, age, severity of the disease, cardiovascular and metabolic comorbidities, and previous and simultaneous systemic treatments on weight changes, was analysed. Weight gain was defined as an increment of more than 2% of baseline weight.

Results  Overall, 191 psoriatic patients (males: 68.6%; mean age: 46.9 years) were included. Mean weight gain was 1.6 kg (2.1%) after 1 year of IFX. Half (48.2%) suffered from a weight gain, and 9.9% from a weight increment of 10% or more. Baseline weight and Body Mass Index, and cardiovascular and metabolic comorbidities did not influence weight. Men (P = 0.007) and patients with severe psoriasis (BSA, P = 0.005) had a tendency to put on weight. Patients with a hospital dietary follow-up (P = 0.01; OR = 0.36 [0.16–0.79]) and patients on methotrexate (P = 0.03; OR = 0.41 [0.18–0.93]) during IFX treatment are thinner, in a multivariate analysis.

Conclusion  Severe weight increment is frequent on IFX treatment, mainly in men, and patients with severe psoriasis. Dietary follow-up or simultaneous use of methotrexate could limit this weight increment.

Ancillary